Equity Profile

BCRX

BIOCRYST PHARMACEUTI

Health CareBiotechnology$2.1B

Aug3Mon

Pre-Earnings Brief

UpcomingQ2-2026Pre-Market9:00 AM EDT

Company Snapshot

BioCryst Pharmaceuticals, Inc. is a biotechnology company focused on developing innovative treatments for rare diseases....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and financial health, which investors closely monitor.

N/A

Revenue Growth

Revenue growth reflects the company's ability to expand its market presence and sales, critical for future investments.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

BCRX Q2-2026 Earnings Preview

Context

Company Snapshot

BioCryst Pharmaceuticals, Inc. is a biotechnology company focused on developing innovative treatments for rare diseases. With a market cap of $2 billion, it operates in the health care sector, where advancements in drug development are crucial for addressing unmet medical needs.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

63%

Avg EPS Surprise

-346.07%

Avg Stock Reaction

+1.71%

Last Quarter Recap

In Q1 2026, BioCryst reported an EPS of -$2.98, which was a significant miss compared to expectations. The stock reacted negatively, declining by 2.21% the following day.

Management Promises & Guidance

Focus on advancing clinical trials for key drug candidates.
Commitment to improving operational efficiencies.
Plans to enhance investor communication regarding future developments.

Expectations

Wall Street Expectations

Overall, expectations for BioCryst's upcoming earnings are cautious, especially following a significant EPS miss last quarter. Investors are looking for signs of recovery and progress in clinical trials.

Bull Case

If the company can report better-than-expected clinical trial results and show signs of revenue growth, it could lead to a positive market reaction.

Bear Case

Conversely, if the company fails to provide clear updates on its drug pipeline or reports further losses, investor confidence may wane.

Expectations

Two Questions That Matter

The print will turn on these two things.

What updates can management provide on the progress of clinical trials?

Investors will closely watch for any advancements in clinical trials, as these can significantly influence the company's future prospects.

How does management plan to address the recent financial losses?

Understanding the company's strategy to improve profitability will be crucial for investor confidence moving forward.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may underestimate the potential impact of upcoming clinical trial results, which could significantly shift investor sentiment.

Supporting Evidence

The recent EPS miss may have overshadowed positive developments in drug trials that could lead to future growth.

Options pricing reflects lower expected volatility, which may not align with the potential for significant news.

The company's historical performance shows a tendency to recover quickly from setbacks, suggesting potential for a rebound.

Key Risk

If clinical trial results exceed expectations, it could dramatically change the narrative around the company's future.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is debating whether BioCryst can turn around its recent poor performance and regain investor trust.

Bull Confirmed If

Positive updates on clinical trials leading to potential partnerships or increased investor interest.

Bear Confirmed If

Continued financial losses without a clear recovery plan, indicating deeper operational issues.

Pre-Earnings Positioning

Options Market

Implied Move

±6.59%

Historical Avg

±9.5%

Pricing rich

The options market is pricing in a move of about 6.59%, indicating uncertainty around the earnings report.

Options are pricing ±28.5% while BCRX has averaged ±9.5% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.7%

30d HV

53.1%

Calls (128K)P/C Ratio: 0.23Puts (28K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If BioCryst beats expectations, history suggests the stock could rise by an average of 7.73%, confirming a positive outlook.

In-Line / Cautious

A cautious but in-line report may lead to muted reactions, as investors await clearer guidance.

Miss

If the company misses again, history suggests a decline of about 8.34%, which could further erode investor confidence.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on the status of key clinical trials and any potential partnerships.
2Management's strategy for addressing recent financial losses.
3Any new product launches or developments in the pipeline.
4Insights into operational efficiencies and cost management efforts.
5Future guidance on revenue expectations and market strategy.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Jul31

SONYBMO

Sony Group Corporation

PreviewView

Jul31

ENBBMO

Company Snapshot

BioCryst Pharmaceuticals, Inc. is a biotechnology company focused on developing innovative treatments for rare diseases....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and financial health, which investors closely monitor.

N/A

Revenue Growth

Revenue growth reflects the company's ability to expand its market presence and sales, critical for future investments.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

BCRX Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

63%

Avg EPS Surprise

-346.07%

Avg Stock Reaction

+1.71%

Last Quarter Recap

In Q1 2026, BioCryst reported an EPS of -$2.98, which was a significant miss compared to expectations. The stock reacted negatively, declining by 2.21% the following day.

Management Promises & Guidance

Focus on advancing clinical trials for key drug candidates.
Commitment to improving operational efficiencies.
Plans to enhance investor communication regarding future developments.

Expectations

Wall Street Expectations

Bull Case

If the company can report better-than-expected clinical trial results and show signs of revenue growth, it could lead to a positive market reaction.

Bear Case

Conversely, if the company fails to provide clear updates on its drug pipeline or reports further losses, investor confidence may wane.

Expectations

Two Questions That Matter

The print will turn on these two things.

What updates can management provide on the progress of clinical trials?

Investors will closely watch for any advancements in clinical trials, as these can significantly influence the company's future prospects.

How does management plan to address the recent financial losses?

Understanding the company's strategy to improve profitability will be crucial for investor confidence moving forward.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may underestimate the potential impact of upcoming clinical trial results, which could significantly shift investor sentiment.

Supporting Evidence

The recent EPS miss may have overshadowed positive developments in drug trials that could lead to future growth.

Options pricing reflects lower expected volatility, which may not align with the potential for significant news.

The company's historical performance shows a tendency to recover quickly from setbacks, suggesting potential for a rebound.

Key Risk

If clinical trial results exceed expectations, it could dramatically change the narrative around the company's future.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is debating whether BioCryst can turn around its recent poor performance and regain investor trust.

Bull Confirmed If

Positive updates on clinical trials leading to potential partnerships or increased investor interest.

Bear Confirmed If

Continued financial losses without a clear recovery plan, indicating deeper operational issues.

Pre-Earnings Positioning

Options Market

Implied Move

±6.59%

Historical Avg

±9.5%

Pricing rich

The options market is pricing in a move of about 6.59%, indicating uncertainty around the earnings report.

Options are pricing ±28.5% while BCRX has averaged ±9.5% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.7%

30d HV

53.1%

Calls (128K)P/C Ratio: 0.23Puts (28K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If BioCryst beats expectations, history suggests the stock could rise by an average of 7.73%, confirming a positive outlook.

In-Line / Cautious

A cautious but in-line report may lead to muted reactions, as investors await clearer guidance.

Miss

If the company misses again, history suggests a decline of about 8.34%, which could further erode investor confidence.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on the status of key clinical trials and any potential partnerships.
2Management's strategy for addressing recent financial losses.
3Any new product launches or developments in the pipeline.
4Insights into operational efficiencies and cost management efforts.
5Future guidance on revenue expectations and market strategy.